Lubiprostone is a locally acting chloride channel activator, specifically a type-2 chloride channel (ClC-2) activator, used primarily for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. It works by increasing intestinal fluid secretion, which softens stool and promotes bowel motility without systemic effects on gut motility. In the Indian context, it is a prescription-only medicine used for patients who have not responded adequately to conventional laxatives.
Adult: For CIC: 24 mcg twice daily with food. For IBS-C: 8 mcg twice daily with food. Note: The 8mcg strength is specifically indicated for IBS-C.
Note: Administer orally twice daily with food and water to reduce the incidence of nausea. Swallow the soft gelatin capsule whole; do not break, crush, or chew. Can be taken with or without other laxatives as directed by a physician.
Lubiprostone acts locally on the apical membrane of epithelial cells lining the gastrointestinal tract. It selectively activates type-2 chloride channels (ClC-2), leading to an increase in chloride ion secretion into the intestinal lumen. This chloride secretion is followed by passive paracellular movement of sodium ions and water into the lumen, resulting in a net increase in intestinal fluid secretion. This softens the stool, increases stool volume, and promotes peristalsis, thereby facilitating bowel movements without directly stimulating colonic smooth muscle.
Pregnancy: Category C (US FDA). Animal studies have shown fetal loss. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Not recommended in India unless clearly needed.
Driving: Lubiprostone is unlikely to affect the ability to drive and use machines. However, patients who experience dizziness or syncope should not drive or operate machinery until symptoms resolve.
| Antidiarrheal agents (e.g., Loperamide, Diphenoxylate/Atropine) | Pharmacodynamic antagonism; may reduce efficacy of lubiprostone. | Moderate |
| Drugs that affect GI motility (e.g., anticholinergics, opioids) | May counteract the pro-secretory effect of lubiprostone. | Moderate |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Theoretical increased risk of GI mucosal irritation; no clinically significant PK interaction. | Minor |
| Proton Pump Inhibitors (e.g., Omeprazole) | No significant pharmacokinetic interaction expected. | None |